Published in Gastroenterology on April 01, 1992
Biochemical analysis of the stress protein response in human oesophageal epithelium. Gut (1997) 1.50
Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. Proc Natl Acad Sci U S A (1993) 1.40
Molecular biology of Barrett's adenocarcinoma. Ann Surg (2001) 1.17
Impact of tumor progression on cancer incidence curves. Cancer Res (2012) 1.13
p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci (1997) 1.01
Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Gut (1994) 0.99
Signaling pathways in the molecular pathogenesis of adenocarcinomas of the esophagus and gastroesophageal junction. Cancer Biol Ther (2013) 0.96
Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg (1997) 0.93
Diagnosis and grading of dysplasia in Barrett's oesophagus. J Clin Pathol (2006) 0.93
Overexpression of p53 protein in Barrett's syndrome with malignant transformation. J Clin Pathol (1993) 0.91
The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus. Ann Surg (1995) 0.89
Biology of Barrett's esophagus and esophageal adenocarcinoma. Gastrointest Endosc Clin N Am (2011) 0.88
c-erbB-2 overexpression in the dysplasia/carcinoma sequence of Barrett's oesophagus. J Clin Pathol (1995) 0.87
p53 protein accumulation in oesophageal squamous cell carcinomas and precancerous lesions. J Clin Pathol (1995) 0.86
Barrett's esophagus. Dig Dis Sci (2000) 0.82
Evaluation of a 4-protein serum biomarker panel-biglycan, annexin-A6, myeloperoxidase, and protein S100-A9 (B-AMP)-for the detection of esophageal adenocarcinoma. Cancer (2014) 0.80
Role of p53 assessment in management of Barrett's esophagus. Dig Dis Sci (1999) 0.80
Barrett's esophagus and adenocarcinoma: from the family to the gene. Gastroenterology (1992) 0.78
Risk factors associated with Barrett's epithelial dysplasia. World J Gastroenterol (2014) 0.77
Barrett's esophagus: model of neoplastic progression. World J Surg (2003) 0.75
Flow-cytometric assessment of regulatory peptides in Barrett's mucosa. Gastroenterology (1992) 0.75
Expression of p53 in urothelial cell cultures from tumour-bearing and tumour-free patients. Br J Cancer (1995) 0.75
[Barrett's esophagus. An update]. Pathologe (2012) 0.75
Genetic control of the cell division cycle in yeast. Science (1974) 13.83
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol (1983) 8.24
An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Gastroenterology (1993) 5.41
Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology (1999) 4.41
Colonoscopic surveillance reduces mortality from colorectal cancer in ulcerative colitis. Gastroenterology (1993) 4.41
A p53-dependent mouse spindle checkpoint. Science (1995) 4.01
Regulation of mating in the cell cycle of Saccharomyces cerevisiae. J Cell Biol (1977) 3.68
Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol (1988) 3.67
Pneumatosis intestinalis: a review. Am J Gastroenterol (1995) 3.48
Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet (1999) 3.30
Endoscopic radiofrequency ablation for Barrett's esophagus: 5-year outcomes from a prospective multicenter trial. Endoscopy (2010) 3.12
Heterogeneity among T cells in intracellular free calcium responses after mitogen stimulation with PHA or anti-CD3. Simultaneous use of indo-1 and immunofluorescence with flow cytometry. J Immunol (1986) 3.08
Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol (2000) 2.99
Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med (1999) 2.77
Physicians' perceptions of dysplasia and approaches to surveillance colonoscopy in ulcerative colitis. Am J Gastroenterol (1995) 2.73
Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia. Am J Gastroenterol (2000) 2.58
Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology (1992) 2.57
Mutations in the p53 gene: an early marker of neoplastic progression in ulcerative colitis. Gastroenterology (1994) 2.55
17p (p53) allelic losses, 4N (G2/tetraploid) populations, and progression to aneuploidy in Barrett's esophagus. Proc Natl Acad Sci U S A (1996) 2.53
Crosslinking of surface antigens causes mobilization of intracellular ionized calcium in T lymphocytes. Proc Natl Acad Sci U S A (1987) 2.53
DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology (1992) 2.48
Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology (1985) 2.44
Neoplastic progression in ulcerative colitis: histology, DNA content, and loss of a p53 allele. Gastroenterology (1992) 2.35
Endoscopic fluorescence detection of high-grade dysplasia in Barrett's esophagus. Gastroenterology (1996) 2.23
Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med (2001) 2.22
Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol (2001) 2.21
CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood (1990) 2.21
Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol (2001) 2.17
Barrett's esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology (1987) 2.15
Targeted gene walking polymerase chain reaction. Nucleic Acids Res (1991) 2.14
Genome-wide detection of allelic imbalance using human SNPs and high-density DNA arrays. Genome Res (2000) 2.13
Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus. Am J Clin Pathol (1978) 2.13
From Dukes through Jass: pathological prognostic indicators in rectal cancer. Hum Pathol (1994) 2.09
Endoscopic biopsy can detect high-grade dysplasia or early adenocarcinoma in Barrett's esophagus without grossly recognizable neoplastic lesions. Gastroenterology (1988) 2.06
p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res (2001) 2.06
Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med (2000) 2.05
Barrett's esophagus: cell cycle abnormalities in advancing stages of neoplastic progression. Gastroenterology (1993) 2.00
Cancer surveillance in ulcerative colitis. Gastroenterology (1991) 1.93
Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst (1990) 1.92
Hereditary gastrointestinal polyposis syndromes. Am J Surg Pathol (1986) 1.91
Malignant epithelioid hemangioendothelioma of the liver in young women. Relationship to oral contraceptive use. Am J Surg Pathol (1985) 1.91
Loss of heterozygosity analysis using whole genome amplification, cell sorting, and fluorescence-based PCR. Genome Res (1999) 1.90
Antibody binding to CD5 (Tp67) and Tp44 T cell surface molecules: effects on cyclic nucleotides, cytoplasmic free calcium, and cAMP-mediated suppression. J Immunol (1986) 1.89
Organization of the sacral parasympathetic reflex pathways to the urinary bladder and large intestine. J Auton Nerv Syst (1981) 1.88
An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants. Hum Genet (1997) 1.88
Progression to cancer in Barrett's esophagus is associated with genomic instability. Lab Invest (1989) 1.83
Risk and natural history of colonic neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis. Gastroenterology (1996) 1.82
Long-term management of gastro-oesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol (2000) 1.81
Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry (1993) 1.77
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis. Cancer Res (1996) 1.74
Gastric cancer. Contemporary aspects. Am J Surg (1977) 1.72
Werner syndrome lymphoblastoid cells are sensitive to camptothecin-induced apoptosis in S-phase. Hum Genet (1999) 1.71
Histologic correlates of gastrointestinal ultrasound images. Gastroenterology (1989) 1.69
Signal transduction through CD4 receptors: stimulatory vs. inhibitory activity is regulated by CD4 proximity to the CD3/T cell receptor. Eur J Immunol (1988) 1.68
p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res (1997) 1.67
Loss of heterozygosity involves multiple tumor suppressor genes in human esophageal cancers. Cancer Res (1992) 1.65
A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology (1995) 1.65